Clinical Scorecard: Pre-existing and Vaccination-Related Immune Impairment in Multiple Myeloma: Insights from a COVID-19 Case Study
At a Glance
Category
Detail
Condition
Multiple Myeloma (MM) with immune impairment and infection risk
Key Mechanisms
Tumor- and treatment-related immunosuppression causing B-cell depletion, altered T-cell subsets, and impaired antigen-presenting cells
Target Population
Patients with multiple myeloma, especially those undergoing treatment
Care Setting
Hematology and oncology clinical settings managing MM patients
Key Highlights
MM patients have a 7-fold increased risk of infections compared to matched controls, with infection being the leading cause of morbidity and mortality.
COVID-19 causes more severe complications and higher mortality in MM patients; vaccine immunogenicity is less potent and durable in this population.
Immune profiling reveals significant alterations in 73% of immune cell subsets in MM patients, notably depletion of B cells and altered T-cell and antigen-presenting cell compartments.
Guideline-Based Recommendations
Diagnosis
Use multidimensional flow cytometry immune profiling to assess immune cell subset alterations in MM patients.
Monitor immunoparesis and immune cell composition prior to and during vaccination.
Management
Consider more frequent COVID-19 vaccine boosters for MM patients due to reduced vaccine immunogenicity and durability.
Tailor vaccination schedules based on individual immune profiling rather than fixed calendars.
Monitoring & Follow-up
Longitudinal monitoring of SARS-CoV-2-specific antibodies (IgM, IgG, IgA) and virus-specific CD8+ T-cells post-vaccination.
Regular assessment of B-cell, T-cell, and antigen-presenting cell subsets to evaluate immune competence.
Risks
High risk of severe infections including COVID-19, especially with T-cell redirecting therapies and BCMA-targeted treatments.
Increased mortality risk from infections in MM patients, necessitating vigilant infection prevention and management.
Patient & Prescribing Data
Multiple myeloma patients undergoing various treatment regimens including BCMA-targeted therapies
Profound hypogammaglobulinemia and immune cell alterations contribute to increased infection risk; vaccination strategies should be individualized and may require more frequent boosters.
Clinical Best Practices
Implement immune profiling using multidimensional flow cytometry to guide vaccination timing and predict vaccine efficacy.
Monitor immune cell subsets longitudinally to detect immune impairment and adjust clinical management accordingly.
Prioritize infection prevention strategies in MM patients, especially during active treatment phases.
Educate patients on the importance of vaccination and potential need for additional booster doses.
by Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, Anastasiia Zherniakova, Aintzane Zabaleta, Catarina Maia, Laura Blanco, Diego Alignani, Maria-Antonia Fortuño, Carlos Grande, Andrea Manubens, Jose-Maria Arguiñano, Clara Gomez, Ernesto Perez-Persona, Iñigo Olazabal, Itziar Oiartzabal, Carlos Panizo, Felipe Prosper, Jesus F. San-Miguel, Paula Rodriguez-Otero, Bruno Paiva
